

4DMedical appoints former CEO of GE Healthcare to senior leadership team

8 December 2022

Highlights

- 4DMedical has appointed highly respected medical imaging executive, Matt Tucker, as Senior Vice President of Business Development and Strategy.
- Matt Tucker was previously Chief Executive Officer and President of GE Healthcare – ANZ where he managed a P&L of approximately \$500m.
- Matt will use his proven expertise and experience in bringing medical imaging platform technologies to market to lead the commercialisation of 4DMedical's XV Scanner.
- 4DMedical's revolutionary XV Scanner, which enables imaging at scale on a pay-per-scan revenue basis, is now entering its early commercialisation stage.

Melbourne, Australia, 8 December 2022: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, "4DMedical", or the "Company") today announces the appointment of experienced medical imaging executive, Matt Tucker, as Senior Vice President of Business Development and Strategy.

The XV Scanner is the world's first and only dedicated lung function scanner, integrating 4DMedical's proprietary XV Technology® into a purpose-built hardware platform. This revolutionary hardware enables imaging in high volumes, and broadens access to additional patient cohorts, including children and other patients whose physical condition inhibits the use of existing diagnostic technology.

A highly experienced executive with a successful track record

Mr Tucker is a highly experienced senior executive with extensive medical imaging knowledge. This skillset has been gained in a career working for several leading global healthcare companies including GE Healthcare, SonoSite and Philips. During his tenure as Chief Executive Officer and President of GE Healthcare, Matt occupied a high-profile role in the Australian medical technology sector and delivered growth across key metrics including revenue generation, customer satisfaction and retention, and profitability. He had earlier played an important role in GE Healthcare's successful turnaround strategy, which saw the company achieve market leadership across the ultrasound product space.

Importantly, Matt's knowledge of medical imaging products runs deep. As well as working for companies selling such medical equipment, he has also operated them in a clinical capacity, working as a sonographer and radiographer early in his career.

Mr Tucker will make a valuable contribution to the ongoing development and execution of the XV Scanner's commercialisation rollout. 4DMedical also expects to leverage Matt's influential voice in the medical technology industry, his global network, and his reputation for creating management strategies that achieve success in complex and challenging markets.




XV Scanner is now entering early-stage commercialisation

XV Scanners are made in Port Melbourne at 4DMedical's manufacturing facility located within the Fishermans Bend Innovation Precinct, with the first prototype XV Scanner being delivered to the University of New South Wales at the Prince of Wales Hospital in Sydney in March earlier this year.

Last week, the XV Scanner made its U.S. debut at the RSNA 2022 conference, which is convened by the Radiological Society of North America and is the world's largest gathering for the medical imaging profession.

The XV Scanner is funded by a \$28.9 million grant provided by the Medical Research Future Fund (MRFF). Under the terms of the deed of grant, full and exclusive commercialisation rights for the XV Scanner product are retained by 4DMedical as the developer and manufacturer of the platform.



The XV Scanner is a unique piece of hardware specifically designed to utilise 4DMedical's proprietary XV Technology® on a pay-per-scan basis. It overcomes the limitations of existing diagnostics and imaging tools by providing low dose, contrast-free, rapid lung analysis. The device delivers detailed quantitative data on respiratory function via an automated scanning process, providing unprecedented insight to clinicians, researchers and patients.

4DMedical CEO and Founder Andreas Fouras said:

We are thrilled Matt has decided to join 4DMedical's senior leadership team. He will play a key role in the Company's efforts to accelerate the commercialisation of our XV Scanner. Success here will drive 4DMedical's revenue growth through increased uptake of our XV Technology® Software-as-a-Service (SaaS) product.

Matt Tucker's reputation, experience and demonstrated success in medical imaging will be a catalyst for 4DMedical to deliver on both the clinical and commercial potential of the world's first dedicated lung imaging platform.



Newly appointed 4DMedical SVP Business Development and Strategy, Matt Tucker, said:

I am excited to join 4DMedical at this key point in its development journey. I first met Andreas in Chicago at RSNA 2016 to facilitate an introduction to showcase his innovation and have followed 4DMedical's progress ever since. I have seen the clinical challenges in diagnosing lung disease, so it feels natural to combine this clinical need with my extensive healthcare business experience to join the team. The Software-as-a-Service (SaaS) XV Technology® product is already well into its commercialisation phase. Now the XV Scanner will soon create an additional revenue stream for the Company. I look forward to using my experience in bringing medical technologies to market to accelerate the commercialisation of 4DMedical's ground-breaking XV Scanner.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

CFO

Simon Glover

sglover@4dmedical.com

Administration

Company Secretary

Melanie Leydin

companysecretary@4dmedical.com

Media Enquiries

TCN

Julia Maguire

julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®), the first modality to dynamically quantify ventilation throughout the lungs.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

To learn more, please visit www.4dmedical.com.